Spinraza is available in Australia for SMA treatment via the PBS, with no major restrictions beyond a 5q SMA diagnosis. Eligible patients (citizens/permanent residents) with a valid prescription can access it at subsidized rates ($41 or $6.60 with concession). Coverage includes both symptomatic and pre-symptomatic patients, recently expanded to pre-symptomatic babies with 1-3 SMN2 gene copies for early intervention.